Furosemide reverses multidrug resistance status in bladder cancer cells in vitro
Furosemide reverses multidrug resistance status in bladder cancer cells in vitro
BACKGROUND: Multidrug resistance (MDR) has a potentially serious influence on cancer treatment and should be taken into consideration in the design and application of therapeutic regimens. It is mediated through the activity of cellular pumps.
AIM: To investigate whether furosemide, itself a pump-blocker, reverses MDR in an in vitro model.
MATERIALS AND METHODS: An MDR bladder cancer cell line (MGH-u 1R) and its parental (drug sensitive) clone were exposed to epirubicin and furosemide, with the concentration of one drug fixed and that of the other serially diluted in a 96-well plate format. Both drugs formed the variable component in separate experiments. After a 1-h exposure, the cells were washed and replenished with fresh medium. To examine the toxicity of epirubicin and furosemide separately and in combination, monotetrazolium-based assays were carried out. Intracellular epirubicin distribution was assessed by confocal microscopy as a second index of resistance status after in vitro exposure.
RESULTS: MGH-u 1R cells incubated with furosemide showed distribution of drug similar to that in the parental cells (MGH-u 1 sensitive). Controls (without furosemide) continued to show a resistant pattern of fluorescence. In cytotoxicity assays furosemide appeared substantially non-toxic. Resistant cells in the toxicity titration experiments showed increased resistance to levels of furosemide over 500 mug/ml. Parental cells were made only marginally more sensitive against increased background toxicity.
CONCLUSION: Furosemide is effective in reversing MDR status in bladder cancer cell lines in vitro. It may also have an increment of intrinsic cytotoxicity, but only at higher concentrations. We propose a potential for further investigation of furosemide as an adjunct to chemotherapy for superficial bladder cancer.
912-915
Speers, A.G.
463d8d1b-6bc5-4352-9493-35783dbbe92f
Lwaleed, B.A.
e7c59131-82ad-4a14-a227-7370e91e3f21
Featherstone, J.M.
abbcbcea-0954-43fc-850b-04aba2dba056
Sallis, B.J.
e1e47c7a-8ad4-4ffa-a684-177a240806cc
Cooper, A.J.
8a21c297-eda3-4479-8e81-1de258c8e2a1
September 2006
Speers, A.G.
463d8d1b-6bc5-4352-9493-35783dbbe92f
Lwaleed, B.A.
e7c59131-82ad-4a14-a227-7370e91e3f21
Featherstone, J.M.
abbcbcea-0954-43fc-850b-04aba2dba056
Sallis, B.J.
e1e47c7a-8ad4-4ffa-a684-177a240806cc
Cooper, A.J.
8a21c297-eda3-4479-8e81-1de258c8e2a1
Speers, A.G., Lwaleed, B.A., Featherstone, J.M., Sallis, B.J. and Cooper, A.J.
(2006)
Furosemide reverses multidrug resistance status in bladder cancer cells in vitro.
Journal of Clinical Pathology, 59 (9), .
(doi:10.1136/jcp.2005.033100).
(PMID:16556663)
Abstract
BACKGROUND: Multidrug resistance (MDR) has a potentially serious influence on cancer treatment and should be taken into consideration in the design and application of therapeutic regimens. It is mediated through the activity of cellular pumps.
AIM: To investigate whether furosemide, itself a pump-blocker, reverses MDR in an in vitro model.
MATERIALS AND METHODS: An MDR bladder cancer cell line (MGH-u 1R) and its parental (drug sensitive) clone were exposed to epirubicin and furosemide, with the concentration of one drug fixed and that of the other serially diluted in a 96-well plate format. Both drugs formed the variable component in separate experiments. After a 1-h exposure, the cells were washed and replenished with fresh medium. To examine the toxicity of epirubicin and furosemide separately and in combination, monotetrazolium-based assays were carried out. Intracellular epirubicin distribution was assessed by confocal microscopy as a second index of resistance status after in vitro exposure.
RESULTS: MGH-u 1R cells incubated with furosemide showed distribution of drug similar to that in the parental cells (MGH-u 1 sensitive). Controls (without furosemide) continued to show a resistant pattern of fluorescence. In cytotoxicity assays furosemide appeared substantially non-toxic. Resistant cells in the toxicity titration experiments showed increased resistance to levels of furosemide over 500 mug/ml. Parental cells were made only marginally more sensitive against increased background toxicity.
CONCLUSION: Furosemide is effective in reversing MDR status in bladder cancer cell lines in vitro. It may also have an increment of intrinsic cytotoxicity, but only at higher concentrations. We propose a potential for further investigation of furosemide as an adjunct to chemotherapy for superficial bladder cancer.
This record has no associated files available for download.
More information
e-pub ahead of print date: 23 March 2006
Published date: September 2006
Organisations:
Faculty of Health Sciences
Identifiers
Local EPrints ID: 349258
URI: http://eprints.soton.ac.uk/id/eprint/349258
ISSN: 0021-9746
PURE UUID: d4e7235c-75bb-4023-83dd-afab2123d08e
Catalogue record
Date deposited: 26 Feb 2013 17:00
Last modified: 06 Aug 2024 01:39
Export record
Altmetrics
Contributors
Author:
A.G. Speers
Author:
J.M. Featherstone
Author:
B.J. Sallis
Author:
A.J. Cooper
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics